glp-1 agonist gastroparesis Gastroparesis: Hidden Dangers Beyond C Gastrointestinal manifestations of diabetes mellitus
Description
ELIXA trial included patients with recent cardiovascular event (patients with acute coronary syndrome 180 days before randomization), and although there was no benefit in MACE reduction in lixisenatide treated patients compared to placebo, results revealed cardiovascular safety of lixisenatide in this specific high risk population (38, 40)
No, retatrutide and tirzepatide are not the same
Additionally, major pharmaceutical companies are innovating and developing tailored solutions for the APAC market to meet these rising demands
Thus, the development of an oral GLP1-RA agent would promote medication adherence and quality of life, further consolidating its beneficial effects in real-life clinical practice
[DOI] [PMC free article] [PubMed] [Google Scholar] 6.Drucker DJ, Habener JF, Holst JJ
When paired with healthy habits and personalized support, they can lead to real, lasting progress
